يعرض 1,601 - 1,620 نتائج من 13,266 نتيجة بحث عن '(( significant increase decrease ) OR ( significant ((greater decrease) OR (nn decrease)) ))', وقت الاستعلام: 0.38s تنقيح النتائج
  1. 1601

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  2. 1602

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  3. 1603

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  4. 1604
  5. 1605
  6. 1606
  7. 1607
  8. 1608
  9. 1609
  10. 1610
  11. 1611
  12. 1612
  13. 1613
  14. 1614

    Simulation platform experimental data. حسب Qingsong Zhang (3353270)

    منشور في 2024
    الموضوعات:
  15. 1615
  16. 1616

    Numerical simulation data. حسب Qingsong Zhang (3353270)

    منشور في 2024
    الموضوعات:
  17. 1617
  18. 1618
  19. 1619
  20. 1620

    Fig 4 - حسب Qingsong Zhang (3353270)

    منشور في 2024
    الموضوعات: